Quanterix Corp (QTRX, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Quanterix Corp is a life science company. The company digitizing biomarker analysis with the goal of advancing the science of precision health. Quanterix Corp has a market cap of $363.010 million; its shares were traded at around $17.14 .
For the last quarter Quanterix Corp reported a revenue of $22.9 million, compared with the revenue of $12.18 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $22.9 million, an increase of 30.1% from last year.
The reported loss per diluted share was $1.276 for the year. The Quanterix Corp had an operating margin of -113.69%, compared with the operating margin of -123.46% a year before. The 10-year historical median operating margin of Quanterix Corp is -121.35%. The profitability rank of the company is 2 (out of 10).
At the end of the fiscal year, Quanterix Corp has the cash and cash equivalents of $79.7 million, compared with $29.7 million in the previous year. The long term debt was $4.35 million, compared with $9.34 million in the previous year. Quanterix Corp has a financial strength rank of 5 (out of 10).
For the complete 20-year historical financial data of QTRX, click here.
